Middle East & Africa Lung Cancer Therapy Market Forecast to 2030 - Regional Analysis - By Therapy Type, Indication, and End User

Description

List of Tables

The Middle East & Africa lung cancer therapy market was valued at US$ 964.67 million in 2022 and is expected to reach US$ 2,116.99 million by 2030; it is estimated to grow at a CAGR of 10.3% from 2022 to 2030.

Increase in Cases of Lung Cancer Drive Middle East & Africa Lung Cancer Therapy Market

Lung cancer is among the main causes of mortality across the world. This type of cancer can be treated more effectively if it is diagnosed early. Therefore, people at a high risk of lung cancer need to undergo routine testing to detect the formation of cancerous growth inside their lungs. Globally lung cancer is the most common cancer in men and the second most common cancer in women. According to the World Health Organization (WHO), lung cancer is the leading cause of cancer-related deaths globally, in both men and women. As per the World Cancer Research Fund International, ~2.2 million new lung cancer cases were registered worldwide in 2020.

Lung cancer is among one of the main causes of mortality across the world. Lung cancer screening is a critical component of cancer prevention approaches. The prognosis of lung cancer patients is better when the disease is diagnosed early, so people at high risk of lung cancer are prompted to undergo routine checkups to detect the formation of cancerous growth in their lungs. The socioeconomic conditions, healthcare infrastructure, and methods used to provide healthcare vary greatly throughout the Middle Eastern and African nations. The prevalence of lung cancer is extremely high in these nations and is expected to keep rising in the near future. Thus, the rising incidences of lung cancer are contributing to the initiation of lung cancer therapy programs, which drive market growth. Thus, the rising incidence of lung cancer worldwide is contributing to the research and development activities for lung cancer therapy, which is, in turn, driving the market growth.

Middle East & Africa Lung Cancer Therapy Market Overview

According to the World Health Organization, the number of new cases of lung cancer in Saudi Arabia was estimated to be 1,157 in 2020. According to the National Library of Medicine, in 2022, lung cancer accounts for 3% of all newly diagnosed cancers in Saudi Arabia. The Saudi Lung Cancer Association of Saudi Thoracic Society, in coordination with The National Cancer Center, developed few guidelines to assist healthcare professionals in the country for the management of different aspects of lung cancer prevention. The program focused on the primary prevention through tobacco control was the first aspect for the government-the recommendations encouraged all healthcare professionals to screen patients for smoking and provide counseling or referral to smoking cessation programs. For early diagnosis of patients with symptoms associated with lung cancer, it is expected standard of care to investigate, test, and provide a proper plan of treatment to the patient, if found at risk. Mass screening was also conducted on patients who were at a high risk for developing lung cancer.

Middle East & Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Million)

Middle East & Africa Lung Cancer Therapy Market Segmentation

The Middle East & Africa lung cancer therapy market is segmented based on therapy type, indication, end user, and country.

Based on therapy type, the Middle East & Africa lung cancer therapy market is bifurcated into noninvasive and minimally invasive. The noninvasive segment held a larger share in 2022. The minimally invasive segment is further subsegmented into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others.

By indication, the Middle East & Africa lung cancer therapy market is bifurcated into non-small cell lung cancer and small cell lung cancer. The non-small cell lung cancer segment held a larger share in 2022.

By end user, the Middle East & Africa lung cancer therapy market is segmented into hospitals, oncology clinics, research centers, and others. The hospitals segment held the largest share in 2022.

Based on country, the Middle East & Africa lung cancer therapy market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa lung cancer therapy market in 2022.

Bioventus Inc, Johnson & Johnson, Medtronic Plc, Merck KGaA, Olympus Corp, RF Medical Co Ltd, and Sun Pharmaceutical Industries Ltd are some of the leading companies operating in the Middle East & Africa lung cancer therapy market.

Product Code: BMIRE00029873

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Middle East & Africa Lung Cancer Therapy Market, by Country

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Middle East & Africa Lung Cancer Therapy Market - Key Industry Dynamics

4.1 Market Drivers:
- 4.1.1 Increase in Cases of Lung Cancer
- 4.1.2 Government Initiatives for Screening and Treatment of Lung Cancer
4.2 Market Restraints
- 4.2.1 High Cost of Lung Cancer Therapy
- 4.2.2 Lack of Awareness Regarding the Lung Cancer Therapy:
4.3 Market Opportunities
- 4.3.1 Rising Number of Lung Cancer Therapy in Clinical Trials
4.4 Future Trends
- 4.4.1 Growing Demand for Targeted Therapy
4.5 Impact Analysis:

5. Middle East & Africa Lung Cancer Therapy Market - Global Market Analysis

5.1 Middle East & Africa Lung Cancer Therapy Market Revenue (US$ Mn), 2020 - 2030

6. Middle East & Africa Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

6.1 Overview
6.2 Middle East & Africa Lung Cancer Therapy Market Revenue Share, by Therapy Type, 2022 & 2030 (%)
6.3 Non-Invasive Therapy
- 6.3.1 Overview
- 6.3.2 Non-Invasive Therapy: Middle East & Africa Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Minimally Invasive
- 6.4.1 Overview
- 6.4.2 Minimally Invasive: Middle East & Africa Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- 6.4.3 Middle East & Africa Lung Cancer Therapy Market, by Minimally Invasive, 2020-2030 (US$ Million)

7. Middle East & Africa Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by Indication

7.1 Overview
7.2 Middle East & Africa Lung Cancer Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
7.3 Non-Small Cell Lung Cancer
- 7.3.1 Overview
- 7.3.2 Non-Small Cell Lung Cancer: Middle East & Africa Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Small Cell Lung Cancer
- 7.4.1 Overview
- 7.4.2 Small Cell Lung Cancer: Middle East & Africa Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)

8. Middle East & Africa Lung Cancer Therapy Market - Revenue and Forecast to 2030 - by End User

8.1 Overview
8.2 Middle East & Africa Lung Cancer Therapy Market Revenue Share, by End User, 2022 & 2030 (%)
8.3 Hospitals
- 8.3.1 Overview
- 8.3.2 Hospitals: Middle East & Africa Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Oncology Clinics
- 8.4.1 Overview
- 8.4.2 Oncology Clinics: Middle East & Africa Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Research Centers
- 8.5.1 Overview
- 8.5.2 Research Centers: Middle East & Africa Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: Middle East & Africa Lung Cancer Therapy Market - Revenue and Forecast to 2030 (US$ Million)

9. Middle East & Africa Lung Cancer Therapy Market - Country Analysis

9.1 Overview

10. Middle East & Africa Lung Cancer Therapy Market - Industry Landscape

10.1 Overview
10.2 Growth Strategies in Middle East & Africa Lung Cancer Therapy Market
10.3 Inorganic Growth Strategies
- 10.3.1 Overview
10.4 Organic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Medtronic Plc
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 RF Medical Co Ltd
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Johnson & Johnson
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Merck KGaA
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Sun Pharmaceutical Industries Ltd
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Bioventus Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Olympus Corp
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms